GLP-1semaglutideglp-1periodontitisdentistry

Journal of Dental Research review finds no dental endpoints studied in GLP-1 patients

Authors grade preclinical evidence of periodontal benefit against pharmacovigilance reports of xerostomia, dysgeusia and anosmia, mostly with semaglutide.

By Maren Holt · Senior Reporter, GLP-1

Oct 13 20:00 ETSource: Journal of dental research

The wire

01A critical appraisal reports obesity prescriptions for GLP-1 receptor agonists rose 587% from 2019 to 2024, while no prospective study has used a dental outcome as an endpoint.
02Clinicians seeing patients on semaglutide or tirzepatide may encounter dry mouth, taste changes and reflux-linked erosion risk, with nausea reported in 15% to 50% of users.
03Osteoprotective and periodontal findings come almost entirely from in vitro and animal work, with a single retrospective cohort offering limited clinical data.

From the source

GLP-1 Receptor Agonists in Dentistry: Promise, Pitfalls, and Evidence Gaps
Journal of dental research · 2026 Oct 14 · Werner N, Pitchika V, Bumm CV et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42873199/